Trials / Conditions / Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa

25 registered clinical trials studyying Dystrophic Epidermolysis Bullosa — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study NCT06594393	Xinnate AB	Phase 2
Recruiting	Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa NCT06834035	M. Peter Marinkovich	Phase 1 / Phase 2
Not Yet Recruiting	Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART) NCT07011589	M. Peter Marinkovich	Phase 1 / Phase 2
Recruiting	A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa NCT07016750	Krystal Biotech, Inc.	Phase 3
Active Not Recruiting	Evaluation of D-Fi for the Treatment of Wounds Due to DEB NCT06892639	Castle Creek Biosciences, LLC.	Phase 3
Recruiting	MSC EVs in Dystrophic Epidermolysis Bullosa NCT04173650	Aegle Therapeutics	Phase 1 / Phase 2
Active Not Recruiting	Pilot Study of ELK-003 Eye Drops for Treating Ocular Manifestations of Epidermolysis Bullosa NCT06713434	Fundación DEBRA Chile, Niños Piel de Cristal	Phase 1
Recruiting	Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa NCT07230223	Isfahan University of Medical Sciences	Phase 1 / Phase 2
Recruiting	Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa NCT05157958	Anterogen Co., Ltd.	Phase 2
Unknown	Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in NCT05529134	Phoenicis Therapeutics	Phase 1 / Phase 2
Completed	A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa NCT04917874	Krystal Biotech, Inc.	Phase 3
Recruiting	Long-Term Follow-up Protocol NCT04917887	Krystal Biotech, Inc.	—
Completed	Gynecological Follow-up of Patients With Dystrophic Epidermolysis Bullosa (EBD) NCT04757727	Centre Hospitalier Universitaire de Nice	—
Completed	Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB NCT04491604	Krystal Biotech, Inc.	Phase 3
Withdrawn	The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB) NCT04214002	Krystal Biotech, Inc.	—
Terminated	Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis NCT03578029	Lenus Therapeutics, LLC	Phase 2
Completed	To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullos NCT03472287	Castle Creek Pharmaceuticals, LLC	Phase 1
Completed	A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients NCT03536143	Krystal Biotech, Inc.	Phase 1 / Phase 2
Completed	A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial NCT03183934	Anterogen Co., Ltd.	—
Completed	Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa NCT02579369	Anterogen Co., Ltd.	Phase 1 / Phase 2
Completed	Short Term Observational Study in DEB Patients NCT02178969	Shire	—
Withdrawn	Pilot Study Evaluating the Efficiency and the Tolerance of the PDT in the Treatment of Epidermal Dysplasia for NCT02004600	Centre Hospitalier Universitaire de Nice	N/A
Withdrawn	Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa NCT01768026	Lotus Tissue Repair, Inc.	—
Withdrawn	A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa NCT01528306	Healthpoint	Phase 2
Completed	Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa NCT01538862	Vanderbilt University Medical Center	Phase 2